Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
Stomach cancer is especially common among Koreans, with data from the National Cancer Center of Korea identifying it as the most common type of cancer in the country from 1999 to 2018. Although Korea reports a lower overall cancer incidence rate compared to the US and UK, its rate of stomach cancer is nearly 10 times higher. Looking to find potential reasons why, a new study led by Dr. Choi Kui-son of the National Ca.